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effective when a willingness to pay (WTP) was $33,000/QALY
or less and TIO + SFC was more cost-effective when a WTP
exceeded that threshold. The cost-effectiveness was also sensitive
to changes in several variables including the mortality rates and
utilities associated with TIO + SAL and TIO + SFC, as well as
the hospitalization rate associated with TIO + SAL. CONCLU-
SION: When monotherapy with TIO is not effective to control
moderate to severe COPD, adding SFC rather than SAL appears
to be a more reasonable approach from a cost-effectiveness
standpoint in the US health care system. However, the results
were sensitive to changes in several key variables.
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OBJECTIVE: Management of pediatric asthma is known to be
very costly. However, little is known about the costs to the
parent. We aimed to objectively assess employee and dependent
costs for employees with children with asthma (EWCWA)
compared with employees with children without asthma
(EWCWOA). METHODS: A retrospective analysis was con-
ducted using multiple US-based employers’ data from 2001 to
2007. Data included medical claims, pharmacy claims, payroll,
work absence, and demographics. Asthma diagnosis (ICD-9
codes 493.xx) or pharmacy claims for an asthma controller
medication were used to identify employees with asthmatic
dependents aged <12 years for the EWCWA cohort. Employees
in the EWCWOA cohort were identiﬁed based on dependent age
and lack of an asthma diagnosis (ICD-9 code) or pharmacy claim
for a controller medication. The index date in the EWCWA
cohort was deﬁned as the date of ﬁrst asthma diagnosis during
2001 or later; the ﬁrst pediatric medical or pharmacy claim date
was used in the EWCWOA cohort. All costs were adjusted to
2007 dollars and incremental costs (EWCWA—EWCWOA)
were calculated using two-part regression models and presented
for health care and prescriptions. Regression models controlled
for demographics, job information, Charlson Co-morbidity
Index, and geographic region. RESULTS: Data were available for
the EWCWA (dependent age <4 yr: n = 4577; 4–7 yr: n = 4343;
8–11 yr: n = 3954; total <12 yr: n = 11,794) and EWCWOA
(dependent age <4 yr: n = 32,558; 4–7 yr: n = 28,017; 8–11 yr:
n = 27,863; total <12 yr: n = 64,812) cohorts. The incremental
annual costs (EWCWA—EWCWOA) for employees and depen-
dents (health care/prescriptions), respectively, were: dependent
age <4 years: -$56/$73† and $663†/$568†; 4–7 years: $199*/
$109† and $904†/$555†; 8–11 years: $364*/$116† and $1081†/
$586†; <12 years: $154†/$95 and $862/$534 (*P < 0.05,
†P < 0.01). CONCLUSION: Pediatric asthma results in signiﬁ-
cant additional costs for both employees and dependents.
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OBJECTIVE: The prevalence of chronic asthma has tripled
during last two decades in Finland, but overall costs of disease
management have not increased and patient level costs have
decreased signiﬁcantly. We analyzed with comprehensive time
series all expenditures as well as the effectiveness of interventions
such as the national action program (1994–2004) and develop-
ment of pharmacotherapy. METHODS: Finnish registry based
data from 1987 to 2005 was combined to evaluate all costs of
asthma. These included comprehensive health care costs, sick-
leave compensations, disability pensions, and loss of produc-
tivity; all converted to 2004 euros. Several scenarios were
constructed to identify the important changes in care processes
and cost drivers during this period. RESULTS: The number of
patients with valid special reimbursement for asthma medication
increased signiﬁcantly (83,000 to 216,000) during the observa-
tion period yet the overall expenditure of care remained at the
level of 1987, at €240 million. Cost of medications doubled
during study period, but savings were achieved as other
expenditures, mainly hospitalizations, and loss of productivity
decreased by 50 to 75%. Treatment effectiveness increased as
asthma related deaths, disability pensions, sick-leave payments
and institutional care decreased signiﬁcantly (50 to 70%). The
cost-saving scenarios showed that a signiﬁcant part (40%) of
positive effects was attained by launch of new asthma drugs and
asthma pipes from 1989 to 1994. The initiation of the national
care programme with its focus on anti-inﬂammatory treatment
from disease onset, improved diagnostics and more active self
care further increased this positive trend. CONCLUSION: Com-
prehensive assessment of large patient cohorts and long term
economical outcomes is a useful method for evaluation of out-
comes in chronic diseases. Identiﬁcation of different cost drivers
is needed as the cost of new interventions is increasing and their
beneﬁts should ideally be assessed in relation to their broader
societal inﬂuence.
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OBJECTIVE: The prevalence and costs of allergic rhinitis (AR)
in the United States are estimated to be very high. Recently,
research has reported that not all AR symptoms are of equal
importance to patients. In particular, evidence is mounting that
nasal congestion is the most bothersome symptom of AR and
thus may account for most of the burden of illness. However,
unlike AR which has an ICD-9-CM code thus facilitating esti-
mates of burden of illness, the cost of nasal congestion must be
obtained indirectly. The purpose of the present analysis is to
estimate the national costs of AR that are attributable to nasal
congestion. METHODS: Data come from a recent national study
of the effect of AR symptoms on patients’ lives (e.g., sleep,
daytime somnolence, mood, and work and school productivity).
These relative effects of nasal congestion were then applied to
U.S. cost estimates derived from the literature and a national
employer claims database to estimate some of the economic
burden of AR that could be attributed to nasal congestion.
RESULTS: Results suggest that almost three-fourths of the cost
associated with burden of illness related to AR is attributable to
nasal congestion. Thus, approximately $3.4 billion of the $4.8
billion in direct costs for AR and approximately $3.1 billion of
the $4.3 billion in indirect costs for AR can be attributed to nasal
congestion. CONCLUSION: The direct and indirect costs attrib-
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utable to nasal congestion are substantial. These high costs
emphasize the importance of diagnosing and treating nasal
congestion.
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OBJECTIVE: To determine the incremental direct medical
expenditures of treating adult asthma in the United States.
METHODS: Retrospective analysis was conducted using the
2004 Medical Expenditure Panel Survey (MEPS) data. Adult
asthma respondents (age 18 years; n = 1552) were identiﬁed
as those with International Classiﬁcation of Diseases (ICD)-9
diagnosis codes for asthma or those that self-reported as having
asthma in 2004. Incremental total expenditures and expendi-
tures for various categories of resource use, i.e., physician ofﬁce
visits, emergency room visits, outpatient visits, inpatient visits,
medications and other medical expenses associated with
asthma, were estimated using separate multivariate regression
models. The models were adjusted for age, gender, race, ethnic-
ity, education, marital status, geographic region, insurance
status and comorbidities (using the Charlson comorbidity
index). Given the skewed distribution of expenditure variables,
multiple model speciﬁcations including ordinary least squares
regression, generalized linear model (GLM) with Poisson,
gamma and negative binomial variance functions were evalu-
ated. RESULTS: The prevalence of current asthma among
adults in 2004 was estimated at 6.84%, i.e., 14.9 million
persons (95% CI: 6.43% to 7.26%) in the United States. Indi-
viduals with asthma had 68% higher total expenditures than
non-asthmatics after controlling for covariates (RR: 1.68;
p < 0.0001). The annual adjusted mean incremental total expen-
diture associated with asthma was $1953.7 (SE: $500.1; p
<0.0001) per person. Medications accounted for the largest pro-
portion of the total expenditures estimated at $609.4 (SE:
$52.0; p <0.0001), followed by physician ofﬁce visits at $364.3
(SE: $86.9; p <0.0001) and inpatient visits at $297.3 (SE:
$191.2; p = 0.074). CONCLUSION: Given the prevalence of
adult asthma and its associated incremental expenditures, the
annual direct medical expenditure for treating adult asthma is
estimated at $29.2 billion in 2005 USD. This estimated incre-
mental expenditure associated with asthma is more than twice
the cost of asthma reported in previous studies.
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OBJECTIVE: To review up-to-date economic outcomes data in
patients with cystic ﬁbrosis (CF), especially costs related to res-
piratory infection by Pseudomonas aeruginosa (Pa), the leading
cause of morbidity and mortality in CF patients. METHODS: A
systematic search of the MEDLINE database from 1990–2007
was conducted, using the terms “cystic ﬁbrosis” and “cost.”
Selected conference abstracts were also searched. Recent articles
that contained economic data on antibiotic and mucolytic thera-
pies were selected for in-depth review. RESULTS: In-depth
review was performed on 27 articles that examined the economic
impact of inhaled tobramycin (2 articles), the effect of home- vs.
hospital-based antibiotic therapies for pulmonary exacerbations
(4), economic impact of recombinant human deoxyribonuclease
(rhDNase) (10), and cost-of-illness for CF (11). Inhaled tobra-
mycin led to reductions in health care costs that offset 37%–57%
of the drug cost. Home-based antibiotic therapy for exacerba-
tions generally resulted in lower health care costs than hospital-
based administration. Use of rhDNase led to reductions in health
care costs that offset 17%-38% of the drug cost. Cost-of-illness
studies have been conducted in 7 countries; the economic esti-
mates varied widely ($9,000 to $64,000/patient/year; 2006 US
dollars) due to differences in treatment patterns, health systems,
methodologies, and subjects. Most cost-of-illness studies were
retrospective observational studies of direct costs from the per-
spective of a hospital or third-party payer. The largest cost cat-
egories included hospitalizations, out-patient visits, rhDNase and
antibiotics. Disease severity and Pa infection were major deter-
minants of cost. CONCLUSION: Studies show that inhaled
tobramycin and rhDNase partially offset medical costs; home-
based antibiotic therapy likely reduces costs; and direct costs can
be high but vary widely across countries and analytical method-
ologies. Areas for future research include direct comparisons of
inhaled antibiotic therapies, examination of the relationship
between treatment adherence and economic outcomes, and esti-
mation of societal cost-of-illness.
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OBJECTIVE: To conduct a cost-utility analysis by comparing
two scenarios in Japan: smoking cessation counseling by a phy-
sician versus use of varenicline, an oral smoking cessation drug,
in addition to counseling. METHODS: A Markov model was
constructed to analyse life-time medical costs and Quality-
Adjusted Life Years (QALYs) from the perspective of health care
payers. In the Markov model, ﬁve years were set as one cycle.
Both cost and utility were discounted at 3% annually. The cohort
of smokers was classiﬁed by gender and age, and we assumed
that smokers started smoking aged 20 years and received
smoking cessation therapy aged 30, 40, 50, 60, or 70 years. The
health care cost and QALYs were calculated throughout the
term until 90 years. We chose three parameters for sensitivity
analyses—success rate of varenicline, unit price of varenicline
and discount rate. In the base-case analysis, success rates of
varenicline and placebo were assumed to be 37.9% and 25.5%,
respectively, in male smokers, and 22.2% and 16.1%, respec-
tively, in female smokers, based on a randomized controlled trial
conducted in Japan. We chose QALY for outcome measurement.
Quality weight for each tobacco-associated disease was derived
from the literature. RESULTS: It was shown that the scenario
where varenicline was prescribed is more effective and less costly
than giving smoking cessation counseling alone. Varenicline
would save direct medical costs of JPY 26,000 (USD226,
USD1 = JPY115) and increase 0.094 QALY in male smokers.
Regarding the budget impact, varenicline is estimated to save JPY
23.7 billion (USD 206 million) of the medical costs for tobacco-
associated diseases for the whole population. Sensitivity analyses
suggested the robustness of the results. CONCLUSION: Vareni-
cline, the ﬁrst oral treatment for smoking cessation in Japan, is
cost-effective and will contribute to the reduction of medical
costs.
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